Recent research has demonstrated that intravenous gene therapy can significantly extend the lifespan and alleviate symptoms in a feline model of Sandhoff disease, a severe neurodegenerative disorder caused by the deficiency of ß-hexosaminidase (Hex). This disease, which leads to the accumulation of GM2 ganglioside in lysosomes, has no current therapeutic options and typically results in early mortality, often by the age of four.
The study, published in Science Translational Medicine, highlights the potential of gene therapy to address not only Sandhoff disease but also Tay-Sachs disease, which shares similar pathological features. Previous clinical trials have primarily focused on AAV gene therapy delivered via brain injections or cerebrospinal fluid, but this study is the first to evaluate the safety and efficacy of intravenous delivery.
In this investigation, the AAV gene therapy successfully expressed the Hex enzymes necessary for breaking down toxic substances in nerve cells. The results were promising, with treated cats living significantly longer—up to three times longer than untreated counterparts—while also showing improvements in clinical symptoms and reduced central nervous system damage. These findings suggest a viable pathway for translating this therapy into clinical applications for patients suffering from Sandhoff disease.
Get started today with Solo access →
